Menold Daniel 4
4 · CymaBay Therapeutics, Inc. · Filed Jan 16, 2024
Insider Transaction Report
Form 4
Menold Daniel
Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2024-01-16$4.05/sh+10,000$40,500→ 10,000 total - Sale
Common Stock
2024-01-16$23.58/sh−10,000$235,806→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-01-16−10,000→ 135,109 totalExercise: $4.05Exp: 2030-05-14→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.47 to $23.74, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020.